PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
20.80
Current Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.82. Joel Greenblatt would see extra liquidity as a cushion for downturns.
20.38
Quick Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.12. Joel Greenblatt would see a superior short-term safety net.
13.56
Cash Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 0.82. Joel Greenblatt might see a strategic advantage in crisis periods.
-11.40
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
1.95
Short-term coverage of 1.95 versus zero Drug Manufacturers - Specialty & Generic median. Walter Schloss would verify if our cash flow management provides advantages.